The outcome of chronic lymphocytic leukemia patients who relapsed after fludarabine, cyclophosphamide, and rituximab-Reference-Cited by-同舟云学术

The outcome of chronic lymphocytic leukemia patients who relapsed after fludarabine, cyclophosphamide, and rituximab

Published:2013-04-27 Issue:6 Volume:90 Page:479-485
ISSN:0902-4441
Container-title:European Journal of Haematology
language:en
Short-container-title:Eur J Haematol

Author:

Panovská Anna¹,Smolej Lukáš²,Lysák Daniel³,Brychtová Yvona¹,Šimkovič Martin²,Motyčková Monika²,Vodárek Pavel²,Lindtnerová Michaela¹,Trbušek Martin,Malčíková Jitka,Pospíšilová Šárka,Mayer Jiří,Doubek Michael

Affiliation:

1. Department of Internal Medicine - Hematology and Oncology; University Hospital, Brno and Faculty of Medicine; Masaryk University; Brno; Czech Republic

2. 4th Department of Medicine - Hematology; Charles University Hospital and Faculty of Medicine; Hradec Králové; Czech Republic

3. Department of Hematooncology; University Hospital; Plzeň; Czech Republic

Publisher

Wiley

Subject

Hematology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/ejh.12106/fullpdf

Reference25 articles.

1. Chronic lymphocytic leukemia and focusing on epidemiology and management in everyday hematologic practice: recent data from the Czech Leukemia Study Group for Life (CELL);Panovská;Clin Lymphoma Myeloma Leuk,2010

2. Monoallelic and biallelic inactivation of TP53 gene in chronic lymphocytic leukemia: selection, impact on survival and response to DNA damage;Malcikova;Blood,2009

3. Missense mutations located in structural p53 DNA-binding motifs are associated with extremely poor survival in chronic lymphocytic leukemia;Trbusek;J Clin Oncol,2011